Novartis | NOVN - Selling And Administration Expenses


Novartis reported $3.14B in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.58B 316M Mar/2026
Alcon AG USD 882M 19M Mar/2026
Amgen USD 1.58B 354M Mar/2026
AstraZeneca USD 5.06B 455M Mar/2026
Autolus Therapeutics Ltd USD 39.95M 4.16M Mar/2026
Bayer EUR 3.7B 356M Mar/2026
Biogen USD 554.3M 128.2M Mar/2026
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Eli Lilly USD 2.93B 198M Mar/2026
Fresenius EUR 819M 143M Dec/2025
Fresenius Medical Care EUR 749M 36M Mar/2026
Genmab DKK 208M 60M Dec/2025
Gilead Sciences USD 1.45B 326M Mar/2026
GlaxoSmithKline GBP 2.12B 558M Mar/2026
GRIFOLS EUR 281M 5.7M Mar/2026
Hikma Pharmaceutical USD 288M 149M Dec/2025
J&J USD 6.03B 719M Mar/2026
Lakefront Biotherapeutics EUR 35.5M 8.91M Mar/2026
Merck EUR 1.52B 80M Mar/2026
Merck USD 2.67B 180M Mar/2026
Novartis USD 3.14B 296M Mar/2026
Novartis USD 3.44B 132M Dec/2025
Novo Nordisk DKK 13.22B 4.22B Mar/2026
Orion EUR 91.9M 18.8M Mar/2026
Pfizer USD 2.92B 1.16B Mar/2026
Philips EUR 1.18B 121M Mar/2026
Recordati EUR 192.76M 5.52M Mar/2026
Regeneron Pharmaceuticals USD 647.7M 127.3M Mar/2026
Roche Holding CHF 7.28B 3.99B Dec/2025
Sanofi EUR 2.33B 419M Mar/2026
UCB EUR 1.47B 193M Dec/2025